When IL-12 was used on its own, it resulted in similar tumour regression with the N2A-IL-2+IL-12 vaccine with 27% of the tumours undergoing complete regression and an overall response of just 63%, while 37% of animals receiving the IL-12 vaccine grew aggressively. Here, IL2 is linked to neoplasm.